FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer

June 24, 2026 2:10 PM

The U.S. Food and Drug Administration has approved Pfizer Inc.'s (NYSE: PFE) Ibrance (palbociclib) in combination with trastuzumab, with or ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found